Qualigen Therapeutics (NASDAQ:QLGN) Vs. OBSV, TERN, NXTC, VIRX, MNOV, RPHM, LRMR, MIST, ANEB, and BCTX
Should you be buying Qualigen Therapeutics stock or one of its competitors? The main competitors of Qualigen Therapeutics include ObsEva (OBSV), Terns Pharmaceuticals (TERN), NextCure (NXTC), Viracta Therapeutics (VIRX), MediciNova (MNOV), Reneo Pharmaceuticals (RPHM), Larimar Therapeutics (LRMR), Milestone Pharmaceuticals (MIST), Anebulo Pharmaceuticals (ANEB), and BriaCell Therapeutics (BCTX). These companies are all part of the "pharmaceutical preparations" industry.
Qualigen Therapeutics vs.
Qualigen Therapeutics (NASDAQ:QLGN) and Terns Pharmaceuticals (NASDAQ:TERN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, community ranking, earnings, profitability, institutional ownership, dividends and risk.
Terns Pharmaceuticals' return on equity of 0.00% beat Qualigen Therapeutics' return on equity.
8.7% of Qualigen Therapeutics shares are owned by institutional investors. Comparatively, 66.1% of Terns Pharmaceuticals shares are owned by institutional investors. 4.7% of Qualigen Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Terns Pharmaceuticals received 8 more outperform votes than Qualigen Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Qualigen Therapeutics an outperform vote while only 66.67% of users gave Terns Pharmaceuticals an outperform vote.
Qualigen Therapeutics currently has a consensus target price of $6.50, indicating a potential upside of 354.55%. Terns Pharmaceuticals has a consensus target price of $26.50, indicating a potential upside of 295.52%. Given Qualigen Therapeutics' higher probable upside, equities research analysts plainly believe Qualigen Therapeutics is more favorable than Terns Pharmaceuticals.
In the previous week, Qualigen Therapeutics had 1 more articles in the media than Terns Pharmaceuticals. MarketBeat recorded 1 mentions for Qualigen Therapeutics and 0 mentions for Terns Pharmaceuticals. Qualigen Therapeutics' average media sentiment score of 0.42 beat Terns Pharmaceuticals' score of 0.00 indicating that Qualigen Therapeutics is being referred to more favorably in the media.
Summary
Qualigen Therapeutics beats Terns Pharmaceuticals on 6 of the 11 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding QLGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment >-1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Qualigen Therapeutics (NASDAQ:QLGN) vs. Its Competitors
Qualigen Therapeutics Competitors List
